Enzalutamide + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Nonmetastatic Castration-Resistant Prostate Cancer

Conditions

Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate

Trial Timeline

Oct 31, 2013 → Nov 28, 2025

NCT ID

NCT02003924

About Enzalutamide + Placebo

Enzalutamide + Placebo is a phase 3 stage product being developed by Astellas Pharma for Nonmetastatic Castration-Resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02003924. Target conditions include Nonmetastatic Castration-Resistant Prostate Cancer, Prostate Cancer, Cancer of the Prostate.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02677896	Phase 3	Completed	Mar 9, 2016	Jul 31, 2024	Metastatic Hormone Sensitive Prostate Cancer
NCT02528643	Phase 2	Completed	Nov 9, 2015	Feb 9, 2021	Advanced Hepatocellular Carcinoma
NCT02294461	Phase 3	Completed	Apr 23, 2014	Jul 17, 2024	Progressive Metastatic Prostate Cancer
NCT02003924	Phase 3	Completed	Oct 31, 2013	Nov 28, 2025	Nonmetastatic Castration-Resistant Prostate Cancer
NCT01212991	Phase 3	Completed	Sep 16, 2010	Feb 14, 2019	Prostate Cancer
NCT00974311	Phase 3	Completed	Sep 30, 2009	Nov 2, 2017	Castration-Resistant Prostate Cancer

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved